ReviewJournal of nanobiotechnology2026
Research progress of nanoparticles in the diagnosis and treatment of renal ischemia-reperfusion injury.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microglia-vascular interactions after spinal cord injury: regulatory mechanisms and therapeutic advances.Frontiers in immunology · 2026Review
- Plant metabolites: potential treatments for ischemic acute kidney injury.Frontiers in pharmacology · 2026Review
- Research progress of exosomes in renal ischemia-reperfusion injury.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Renal ischemia-reperfusion injury (RIRI) is a prevalent and damaging pathological process in clinical practice, significantly impairing renal recovery and long-term prognosis. The pathogenesis of IRI involves multiple factors, including oxidative stress, inflammatory activation, cell death pathways, and microcirculatory disturbances. Conventional therapies have limited efficacy targeting individual factors and fail to provide comprehensive intervention within the complex RIRI pathological network. Recently, nanoparticles-due to their excellent biocompatibility, targeting ability, and environment-responsive characteristics-have become promising tools for precise diagnosis and multimodal therapy in RIRI. This review systematically summarizes recent advances in nanoparticle-based strategies for RIRI, emphasizing their mechanistic roles in modulating key pathological processes. These mechanisms involve ROS scavenging to reduce oxidative stress, inhibition of NF-κB to suppress inflammation, stabilization of mitochondria to prevent apoptosis, regulation of ferroptosis, and restoration of microcirculatory function. Furthermore, we highlight the potential of nanoparticles in diagnostic applications, such as enhancing lesion-specific localization and molecular imaging accuracy through intelligent stimulus-responsive systems. The article also discusses major challenges in translating nanotechnology clinically, including in vivo stability, biosafety, and large-scale production. Finally, we outline future research directions, such as the development of smart responsive platforms, multi-target synergistic therapeutic systems, and strategies for remodeling the renal immune microenvironment. Overall, this work aims to establish a theoretical foundation to advance nanotechnology's clinical application and mechanistic understanding in RIRI management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.